Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABIO NASDAQ:TIL NASDAQ:TVGN NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$384.99$1.56▼$4.49$34.82M0.91607,995 shs290,800 shsTILInstil Bio$18.51-2.6%$22.83$10.80▼$44.50$128.26M2.07123,516 shs61,070 shsTVGNTevogen Bio$0.63-6.6%$0.82$0.61▼$3.09$132.56M-0.83512,195 shs697,025 shsVTGNVistaGen Therapeutics$4.10-3.1%$3.53$1.90▼$4.52$129.78M0.55533,019 shs676,105 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma0.00%0.00%0.00%0.00%0.00%TILInstil Bio-2.58%-12.27%-4.44%-42.59%-44.88%TVGNTevogen Bio-6.63%-16.63%-24.68%-41.20%-60.92%VTGNVistaGen Therapeutics-3.07%+2.50%+23.12%+51.29%+32.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$384.99$1.56▼$4.49$34.82M0.91607,995 shs290,800 shsTILInstil Bio$18.51-2.6%$22.83$10.80▼$44.50$128.26M2.07123,516 shs61,070 shsTVGNTevogen Bio$0.63-6.6%$0.82$0.61▼$3.09$132.56M-0.83512,195 shs697,025 shsVTGNVistaGen Therapeutics$4.10-3.1%$3.53$1.90▼$4.52$129.78M0.55533,019 shs676,105 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma0.00%0.00%0.00%0.00%0.00%TILInstil Bio-2.58%-12.27%-4.44%-42.59%-44.88%TVGNTevogen Bio-6.63%-16.63%-24.68%-41.20%-60.92%VTGNVistaGen Therapeutics-3.07%+2.50%+23.12%+51.29%+32.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABIOARCA biopharma 0.00N/AN/AN/ATILInstil Bio 2.60Moderate Buy$88.50378.12% UpsideTVGNTevogen Bio 2.00Hold$10.001,489.32% UpsideVTGNVistaGen Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ABIO, TVGN, VTGN, and TIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/22/2025TILInstil BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/14/2025TILInstil BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TILInstil BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TVGNTevogen BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025VTGNVistaGen TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TILInstil BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TVGNTevogen BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VTGNVistaGen TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/11/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.009/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABIOARCA biopharmaN/AN/AN/AN/A$2.25 per shareN/ATILInstil BioN/AN/AN/AN/A$25.96 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($0.09) per shareN/AVTGNVistaGen Therapeutics$490K256.71N/AN/A$2.44 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABIOARCA biopharma-$5.34M-$0.42N/AN/AN/AN/A-20.18%-19.51%N/ATILInstil Bio-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)TVGNTevogen Bio-$13.73M-$0.19N/A∞N/AN/AN/A-775.49%11/18/2025 (Estimated)VTGNVistaGen Therapeutics-$51.42M-$1.78N/AN/AN/AN/A-74.06%-64.10%11/6/2025 (Estimated)Latest ABIO, TVGN, VTGN, and TIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025N/ATILInstil Bio-$2.00N/AN/AN/AN/AN/A11/6/2025Q2 2026VTGNVistaGen Therapeutics-$0.52N/AN/AN/A$0.16 millionN/A8/19/2025N/ATVGNTevogen Bio-$0.05-$0.03+$0.02-$0.03N/AN/A8/13/2025Q2 2025TILInstil Bio-$1.72-$3.24-$1.52-$3.24N/AN/A8/7/2025Q1 2026VTGNVistaGen Therapeutics-$0.47-$0.47N/A-$0.47$0.22 million$0.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABIOARCA biopharmaN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABIOARCA biopharmaN/A26.6126.61TILInstil Bio0.6414.9714.97TVGNTevogen BioN/A0.260.26VTGNVistaGen TherapeuticsN/A5.985.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABIOARCA biopharma56.44%TILInstil Bio60.56%TVGNTevogen BioN/AVTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipABIOARCA biopharma30.90%TILInstil Bio47.20%TVGNTevogen Bio73.24%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABIOARCA biopharma614.51 million10.02 millionOptionableTILInstil Bio4106.75 million3.57 millionNo DataTVGNTevogen Bio3196.71 million52.64 millionN/AVTGNVistaGen Therapeutics4030.68 million29.81 millionOptionableABIO, TVGN, VTGN, and TIL HeadlinesRecent News About These CompaniesVistaGen Therapeutics' (VTGN) "Outperform" Rating Reaffirmed at William BlairOctober 21 at 1:30 PM | marketbeat.comVistagen to Present at The Menopause Society 2025 Annual MeetingOctober 16, 2025 | businesswire.comVistaGen Therapeutics (NASDAQ:VTGN) Given "Sell (D-)" Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comIs Vistagen Therapeutics (NASDAQ:VTGN) In A Good Position To Invest In Growth?September 27, 2025 | finance.yahoo.comJanus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now?September 26, 2025 | msn.comVistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitSeptember 9, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety TrialSeptember 2, 2025 | sg.finance.yahoo.comWhile institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the mostAugust 17, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | msn.comVistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...August 8, 2025 | finance.yahoo.comVistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comQ1 2026 Vistagen Therapeutics Inc Earnings Call TranscriptAugust 8, 2025 | gurufocus.comVistagen (VTGN) Q1 R&D Expense Jumps 54%August 7, 2025 | fool.comVistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue EstimatesAugust 7, 2025 | zacks.comVistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate UpdateAugust 7, 2025 | businesswire.comVistaGen Therapeutics Q1 2026 Earnings PreviewAugust 6, 2025 | msn.comVistagen to Present at the BTIG Virtual Biotechnology ConferenceJuly 24, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABIO, TVGN, VTGN, and TIL Company DescriptionsARCA biopharma NASDAQ:ABIOARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Instil Bio NASDAQ:TIL$18.51 -0.49 (-2.58%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$18.46 -0.05 (-0.27%) As of 10/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Tevogen Bio NASDAQ:TVGN$0.63 -0.04 (-6.63%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$0.63 +0.00 (+0.29%) As of 10/22/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.VistaGen Therapeutics NASDAQ:VTGN$4.10 -0.13 (-3.07%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$4.16 +0.06 (+1.46%) As of 10/22/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
